Evaxion Biotech A/S has entered into an option and licensing agreement with pharmaceutical giant Merck & Co., Inc. for two preclinical vaccine candidates. The deal includes an upfront payment of $3.2 million and potential milestone payments of up to $592 million per product. The collaboration underscores the potential of Evaxion’s AI-Immunology platform and its vaccine candidates.